JCXH-107

JCXH-107 is an mRNA-based vaccine candidate developed by Immorna Biotherapeutics for the prevention of influenza. The therapeutic utilizes Immorna's proprietary mRNA technology, which is delivered into host cells using lipid nanoparticles (LNPs). Once delivered, the mRNA instructs the cells to produce specific influenza viral proteins, such as hemagglutinin, through natural translation mechanisms to stimulate a protective immune response. This approach aims to provide a more rapid and flexible alternative to traditional egg-based influenza vaccine manufacturing, potentially allowing for faster responses to seasonal strain changes or pandemic threats.